updated Sat. September 28, 2024
-
MilTech
December 12, 2017
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy. The market for sepsis therapeutics will be driven by rise in base of geriatric population and growingÃÂ ...
Seeking Alpha
July 23, 2017
In 2011, Eli Lilly (NYSE:LLY) withdrew its previously approved sepsis drug, Xigris, from all markets after the drug, approved a decade previously with a statistically significant efficacy of 6%, failed to replicate the same result in a clinical trial of 1,696 patients. Recently Spectral Medical, Inc. (OTCPK:EDTXF),ÃÂ ...
OUPblog (blog)
April 22, 2016
The two most prominent attempts to clinically reduce the impact of septic shock have been “Centoxin”, a monoclonal antibody product aimed at reducing endotoxin produced by gram negative bacteria and activated protein C (Drotrecogin Alfa, “Xigris”), which was designed to reduce the abnormal clottingÃÂ ...
Indianapolis Star
December 28, 2015
After years of lackluster sales, Lilly made the startling admission in 2011 that Xigris wasn't reducing mortality among the thousands of patients who received it. So the drug was pulled from the market. Stock analysts had predicted Xigris would be a blockbuster with annual sales over $1 billion. But in its lastÃÂ ...
ABC News
July 19, 2012
The only drug developed for it, called Xigris, was withdrawn from the market in 2011, when the drug failed rigorous testing required to maintain regulatory approval. The drug's fall from grace highlights just how difficult fighting sepsis is, and leaves doctors wondering whether developing a drug will ever beÃÂ ...
Nature.com
June 25, 2012
The two compounds are thrombomodulin (Solulin/Recomodulin), currently approved in Japan to prevent thrombosis, and activated protein C (Xigris). Xigris, made by pharmaceutical firm Eli Lilly in Indianapolis, Indiana, was a leading drug for treating inflammation from blood poisoning until it was pulledÃÂ ...
Scientific American (blog)
November 2, 2011
Just last week, I mentioned that Eli Lilly and Company, as a condition of approval for their blockbuster drug, was required to conduct post-marketing studies of Xigris. Yesterday, Lilly unexpectedly announced the withdrawal Xigris from the market. This was not due to adverse events or side effects, but wasÃÂ ...
Markets Insider
November 9, 2017
... where he led the Xigris (activated Protein C) Global Product Team and successfully registered the first drug approved for the treatment of ...
Seeking Alpha
July 23, 2017
In 2011, Eli Lilly (NYSE:LLY) withdrew its previously approved sepsis drug, Xigris, from all markets after the drug, approved a decade ...
OUPblog (blog)
April 22, 2016
... (Drotrecogin Alfa, “Xigris”), which was designed to reduce the abnormal clotting caused by sepsis in capillaries and so reduce organ damage ...
Indianapolis Star
December 28, 2015
After years of lackluster sales, Lilly made the startling admission in 2011 that Xigris wasn't reducing mortality among the thousands of patients ...
Pharmaceutical Processing
March 26, 2015
A new report expects the market value for sepsis treatments to increase more than thirteen-fold between 2016 and 2021 following the launch of ...
ABC News
July 19, 2012
The only drug developed for it, called Xigris, was withdrawn from the market in 2011, when the drug failed rigorous testing required to maintain ...
Nature.com
June 25, 2012
Xigris, made by pharmaceutical firm Eli Lilly in Indianapolis, Indiana, was a leading drug for treating inflammation from blood poisoning until it ...
Scientific American (blog)
November 2, 2011
Xigris, known generically as recombinant activated protein C or drotrecogin alfa activated, was approved by the FDA in 2001—by an evenly ...
Seeking Alpha
July 23, 2017
In 2011, Eli Lilly (NYSE:LLY) withdrew its previously approved sepsis drug, Xigris, from all markets after the drug, approved a decadeÃÂ ...
WebMD
April 4, 2017
April 4, 2017 -- The possibility of curing sepsis with a common vitamin has put one of history's greatest killers back in the spotlight. Sepsis hasÃÂ ...
OUPblog (blog)
April 22, 2016
... (Drotrecogin Alfa, “Xigris”), which was designed to reduce the abnormal clotting caused by sepsis in capillaries and so reduce organ damageÃÂ ...
Indianapolis Star
December 28, 2015
After years of lackluster sales, Lilly made the startling admission in 2011 that Xigris wasn't reducing mortality among the thousands of patientsÃÂ ...
ABC News
July 19, 2012
The only drug developed for it, called Xigris, was withdrawn from the market in 2011, when the drug failed rigorous testing required to maintainÃÂ ...
Nature.com
June 25, 2012
Xigris, made by pharmaceutical firm Eli Lilly in Indianapolis, Indiana, was a leading drug for treating inflammation from blood poisoning until itÃÂ ...
Nature.com
June 25, 2012
Xigris, made by pharmaceutical firm Eli Lilly in Indianapolis, Indiana, was a leading drug for treating inflammation from blood poisoning until itÃÂ ...
Scientific American (blog)
November 2, 2011
Xigris, known generically as recombinant activated protein C or drotrecogin alfa activated, was approved by the FDA in 2001—by an evenlyÃÂ ...
MilTech
March 16, 2017
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy.
Medgadget (blog)
February 20, 2017
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy.
Medgadget (blog)
January 5, 2017
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy.
Medgadget (blog)
November 12, 2016
... very limited treatment options have been introduced into the market over the past decades and the mortality rate due to sepsis related conditions remains high.
Medgadget (blog)
October 19, 2016
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy.
Somewhat Reasonable
December 31, 1999
Seifert Alimta pemetrexed Gemzar gemcitabine hydrochloride ReoPro abciximab Glucagon Humulin Humalog Cymbalta duloxetine hydrochloride Cialis Humatrope Prozac Strattera Symbyax Zyprexa Evista Forteo Xigris. Therefore, administration of CIALIS toÃÂ ...
Somewhat Reasonable
December 31, 1999
Seifert Alimta pemetrexed Gemzar gemcitabine hydrochloride ReoPro abciximab Glucagon Humulin Humalog Cymbalta duloxetine hydrochloride Cialis Humatrope Prozac Strattera Symbyax Zyprexa Evista Forteo Xigris. Sildenafil Citrate Forgotten usernameÃÂ ...
Somewhat Reasonable
December 31, 1999
... and Cialis free trial, for sale 10 mg. Seifert Alimta pemetrexed Gemzar gemcitabine hydrochloride ReoPro abciximab Glucagon Humulin Humalog Cymbalta duloxetine hydrochloride Cialis Humatrope Prozac Strattera Symbyax Zyprexa Evista Forteo Xigris.
Medgadget (blog)
August 25, 2016
Sepsis is a serious medical condition that is characterized by an uncontrolled immune response to an infection and is a leading cause of mortality worldwide.
Medgadget.com (blog)
June 18, 2016
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy.
Medgadget.com (blog)
June 9, 2016
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy.
OUPblog (blog)
April 22, 2016
The two most prominent attempts to clinically reduce the impact of septic shock have been "Centoxin", a monoclonal antibody product aimed at reducing endotoxin produced by gram negative bacteria and activated protein C (Drotrecogin Alfa, "Xigris ...
EconoTimes
April 18, 2016
Earlier in his career, Dr. Levy was Clinical Research Physician and Medical Director, Acute Care in the U.S. Medical Division of Eli Lilly and Company supporting post-marketing clinical trials and medical affairs for recombinant Activated Protein C ...
Medgadget.com (blog)
March 28, 2016
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy.
Nature.com
March 18, 2016
Though sepsis and septic shock cause million death annually worldwide, the only antisepsis agent, Xigris (human recombinant activated protein C/Drotrecogin alfa), was withdrawn from the market after a follow-up placebo-controlled trial due to lack ofÃÂ ...
Medgadget.com (blog)
March 5, 2016
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy.
Medgadget.com (blog)
February 2, 2016
PMR_New_logo_Final26 Sepsis is a serious medical condition that is characterized by an uncontrolled immune response to an infection and is a leading cause of mortality worldwide.
Medgadget.com (blog)
December 28, 2015
The only therapeutic product currently approved in the U.S. for the treatment of sepsis is Xigris. This product is not widely accepted owing to its high cost, adverse effects and concerns about its efficacy.
Indianapolis Star
December 28, 2015
Until Xigris in 2001. Just one problem: It didn't really work as promised. After years of lackluster sales, Lilly made the startling admission in 2011 that Xigris wasn't reducing mortality among the thousands of patients who received it. So the drug ...
|
news and opinion
|
